A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to

See also
Status	Clinical Trial	Phase
Completed	`NCT03236870` - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed	`NCT00078819` - Etanercept (Enbrel®) in Psoriasis - Pediatrics	Phase 3
Completed	`NCT04841187` - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting	`NCT03927352` - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis	Phase 3
Completed	`NCT03284879` - Post-Marketing Surveillance Study of OTEZLA
Recruiting	`NCT06027034` - Effectiveness of a Digital Health Application for Psoriasis	N/A
Not yet recruiting	`NCT06050330` - CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study	N/A
Recruiting	`NCT05744466` - A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Completed	`NCT04149587` - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed	`NCT01384630` - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis	Phase 2
Completed	`NCT03998683` - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis	Phase 3
Terminated	`NCT03556202` - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)	Phase 3
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting	`NCT06077331` - A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis	Phase 2
Completed	`NCT04316585` - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants	Phase 1
Completed	`NCT04894890` - A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed	`NCT00358384` - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034	Phase 1
Completed	`NCT03757013` - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Completed	`NCT03265613` - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis	Phase 1/Phase 2
Completed	`NCT05003531` - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis	Phase 2

NCT number	NCT05645627
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	February 10, 2023
Completion date	April 10, 2025

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms